Pienta K - Search Results

1

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy.

Jackson WC, Feng FY, Daignault S, Hussain M, Smith D, Cooney K, Pienta K, Jolly S, Hollenbeck B, Olson KB, Sandler HM, Ray ME, Hamstra DA. Jackson WC, et al. Among authors: pienta k. Adv Radiat Oncol. 2015 Dec 9;1(1):59-66. doi: 10.1016/j.adro.2015.11.001. eCollection 2016 Jan-Mar. Adv Radiat Oncol. 2015. PMID: 28799570 Free PMC article.

2

Oral etoposide in the treatment of hormone-refractory prostate cancer.

Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Hussain MH, et al. Among authors: pienta kj. Cancer. 1994 Jul 1;74(1):100-3. doi: 10.1002/1097-0142(19940701)74:1<100::aid-cncr2820740118>3.0.co;2-k. Cancer. 1994. PMID: 8004566

3

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urol Clin North Am. 1997 May;24(2):433-7. doi: 10.1016/s0094-0143(05)70390-6. Urol Clin North Am. 1997. PMID: 9126241

4

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC. Pienta KJ, et al. Urology. 1997 Sep;50(3):401-6; discussion 406-7. doi: 10.1016/S0090-4295(97)00228-8. Urology. 1997. PMID: 9301705 Clinical Trial.

5

Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.

Pienta KJ, Smith DC. Pienta KJ, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77. Semin Oncol. 1997. PMID: 9346227 Clinical Trial.

6

Vitamins A and E: further clues for prostate cancer prevention.

Olson KB, Pienta KJ. Olson KB, et al. Among authors: pienta kj. J Natl Cancer Inst. 1998 Mar 18;90(6):414-5. doi: 10.1093/jnci/90.6.414. J Natl Cancer Inst. 1998. PMID: 9521160 No abstract available.

7

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Smith DC, et al. Among authors: pienta kj. J Clin Oncol. 1998 May;16(5):1835-43. doi: 10.1200/JCO.1998.16.5.1835. J Clin Oncol. 1998. PMID: 9586898 Clinical Trial.

8

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urology. 1998 Aug;52(2):257-60. doi: 10.1016/s0090-4295(98)00173-3. Urology. 1998. PMID: 9697791 Clinical Trial.

9

Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer.

Esper P, Hampton JN, Smith DC, Pienta KJ. Esper P, et al. Among authors: pienta kj. Oncol Nurs Forum. 1999 Jan-Feb;26(1):107-12. Oncol Nurs Forum. 1999. PMID: 9921573

10

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Sanda MG, et al. Among authors: pienta kj. Urology. 1999 Feb;53(2):260-6. doi: 10.1016/s0090-4295(98)00539-1. Urology. 1999. PMID: 9933036

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

653 results

Search Page